Methicillin-Resistant *Staphylococcus aureus* Colonization and Risk of Subsequent Infection in Critically Ill Children: Importance of Preventing Nosocomial Methicillin-Resistant *Staphylococcus aureus* Transmission

Aaron M. Milstone,1,2,3 Brian W. Goldner,1 Tracy Ross,4 John W. Shepard,3 Karen C. Carroll,4,5 and Trish M. Perl2,3,5

1Department of Pediatrics, Division of Pediatric Infectious Diseases, Johns Hopkins University School of Medicine, 2Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, 3Department of Hospital Epidemiology and Infection Control, The Johns Hopkins Hospital, 4Department of Pathology, Division of Medical Microbiology, and 5Department of Medicine, Division of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, Maryland

**Background.** Methicillin-resistant *Staphylococcus aureus* (MRSA) colonization is a predictor of subsequent infection in hospitalized adults. The risk of subsequent MRSA infections in hospitalized children colonized with MRSA is unknown.

**Methods.** Children admitted to an academic medical center’s pediatric intensive care unit between March 2007 and March 2010 were included in the study. Anterior nares swabs were cultured to identify children with MRSA colonization at admission. Laboratory databases were queried and National Healthcare Safety Network definitions applied to identify patients with MRSA infections during their hospitalization or after discharge.

**Results.** The MRSA admission prevalence among 3140 children was 4.9%. Overall, 56 children (1.8%) developed an MRSA infection, including 13 (8.5%) colonized on admission and 43 (1.4%) not colonized on admission (relative risk [RR], 5.9; 95% confidence interval [CI], 3.4–10.1). Of those, 10 children (0.3%) developed an MRSA infection during their hospitalization, including 3 of 153 children (1.9%) colonized on admission and 7 of 2987 children (0.2%) not colonized on admission (RR, 8.4; 95% CI, 2.7–25.8). African-Americans and those with public health insurance were more likely to get a subsequent infection (*P* < .01 and *P* = .03, respectively). We found that 15 children acquired MRSA colonization in the pediatric intensive care unit, and 7 (47%) developed a subsequent MRSA infection.

**Conclusions.** MRSA colonization is a risk factor for subsequent MRSA infection in children. Although MRSA colonized children may have lower risks of subsequent infection than adults, children who acquire MRSA in the hospital have similarly high rates of infection. Preventing transmission of MRSA in hospitalized children should remain a priority.

The community prevalence of methicillin-resistant *Staphylococcus aureus* (MRSA) is increasing due in large part to the epidemic of community-associated MRSA strains [1–3]. More children are being hospitalized with MRSA infections, and transmission of MRSA among children may lead to healthcare-associated infections (HAI) [4–10]. In the United States, MRSA causes 8% of all HAI, and MRSA infections are associated with an estimated 18650 deaths annually in hospitalized patients [11, 12].

MRSA colonization in adults is a known risk factor for developing an MRSA infection [13, 14]. Adults who acquire MRSA colonization in the hospital have an even greater risk, up to 30%, of developing a subsequent MRSA infection [15]. In an attempt to prevent MRSA transmission and reduce MRSA infections, many hospitals have implemented comprehensive MRSA control...
programs, including screening high-risk patients for MRSA colonization and placing MRSA carriers in isolation with contact precautions [16]. For children, contact precautions and isolation may hinder family centered care and have unintended and lasting consequences [17]. Despite the increasing number of children colonized or infected with MRSA at time of admission to the hospital, the risk of subsequent infection in hospitalized children colonized with MRSA is unknown. Identifying whether similar risks exist in adults and children would support current pediatric MRSA control programs and inform healthcare workers who counsel families of MRSA-colonized children who worry about their child’s risk of a future infection [18, 19].

Our objective was to measure the risk of developing a subsequent MRSA infection in children colonized with MRSA.

**MATERIALS AND METHODS**

**Setting and Design**
The Johns Hopkins Hospital (JHH) is a 920-bed tertiary-care academic medical center with an embedded 175-bed Children’s Hospital. The 26-bed pediatric intensive care unit (PICU) admits ~1700 medical and surgical patients each year, including hematopoietic stem cell–transplant and organ-transplant patients, as well as cardiac, orthopedic, and neurosurgical patients. Beginning 1 March 2007 naris swabs were performed by nurses to screen patients for MRSA colonization at the time of admission to PICU and weekly thereafter [20]. We retrospectively identified a cohort of patients screened for MRSA colonization on admission to the PICU between 1 March 2007 and 31 March 2010 with a hospital length of stay >2 days. We conducted an observational study to determine the risk of subsequent MRSA infection during each patient’s hospitalization and after discharge, including subsequent hospitalizations. For patients with multiple PICU admissions, the first admission within the study period was considered the patient’s entry into the cohort. The institutional review board approved this study with a waiver of informed consent to review retrospective data.

**Definitions**
MRSA colonization at the time of PICU admission was defined as having an admission naris surveillance culture grow MRSA or any clinical culture grow MRSA within 3 days of PICU admission [21]. Patients were considered previously colonized if they were not colonized at time of admission, but had an institutional history of MRSA colonization or infection. PICU-acquired MRSA cases became MRSA-colonized or MRSA-infected in the PICU and met the following criteria: (1) had a surveillance or clinical culture obtained >3 days after admission to the PICU growing MRSA [22], (2) had no institutional history of MRSA, and (3) had a previous naris culture that did not grow MRSA during the same PICU admission.

**Data Collection and Case Identification**
We queried a computerized surveillance support system (Theradoc) to identify cultures from any body site that grew MRSA between 1 March 2007 and 1 October 2010. The follow-up period included a minimum of 6 months following enrollment and =3.5 years for patients admitted at the start of the study period. 1 study team member (B. G.) reviewed medical records of patients in whom MRSA grew in a culture sent from JHH inpatient units, the JHH emergency department, and JHH outpatient clinics at the discretion of the patient’s treating clinician. National Healthcare Safety Network’s (NHSN’s) surveillance definitions for HAIs were applied to all cultures to distinguish infection versus colonization [23]. Administrative databases were queried and medical records were reviewed to obtain patient characteristics.

**Laboratory Methods**
Surveillance cultures were plated on selective agar and evaluated by pulsed-field gel electrophoresis (PFGE) as previously described [20, 24]. DNA was extracted and digested using SmaI [25, 26]. We used *Staphylococcus aureus* subspecies NCTC 8325 as a control strain, and all USA PFGE strain types were included for comparison [27]. We considered isolates related if their patterns had ≤3 band differences [27] and isolates unrelated if there were >3 band differences. Strains were compared with USA type strains obtained through the Network of Antimicrobial Resistance in *Staphylococcus aureus* (NARS) program supported under NIAID/NIH contract #HHSN272200700055C. CA-MRSA strains included those belonging to the PFGE types USA300 and USA400 [27]. Non–CA-MRSA strains included those belonging to other PFGE types. For isolates not available for strain typing, the original antibiotic susceptibility patterns were reviewed. Strains susceptible to clindamycin and trimethoprim/sulfamethoxazole were considered phenotypic CA-MRSA strains and those resistant to clindamycin or trimethoprim/sulfamethoxazole were considered phenotypic non–CA-MRSA strains based on institutional experience [28, 29].

**Statistical Analysis**
Data were maintained in Microsoft Access (2007) and analyzed using Stata version 11.0 (Stata Corp). Mean, median, and interquartile ranges (IQR) were calculated for select demographic information. Categorical variables were expressed as numbers and percentages. Comparison of the risk of subsequent infection between those colonized with MRSA at time of first PICU admission, and those not colonized with MRSA were made using a 2-sample test of proportions (Pearson $\chi^2$ or Fisher exact test). Kaplan–Meier survival estimates were calculated for patients with and without MRSA colonization, and the log rank test was used to analyze the risk of subsequent MRSA infection during the first hospitalization. A 2-tailed $P$ value of <.05 was considered significant for all statistical tests.
RESULTS

Between 1 March 2007 and 31 March 2010, 3620 patients were admitted to the PICU. Of those admitted, 3140 (87%) were screened for MRSA at the time of admission and were eligible for analysis. The median age was 5.8 years (IQR, 1.0–12.8 years), and 56% were male (see Table 1). Of the 3140 screened, 153 patients (4.9%) were colonized or infected with MRSA at the time of admission to the PICU, including 131 patients (86%) detected by naris surveillance cultures and 22 patients (14%) who had a clinical culture grow MRSA within 3 days of PICU admission. At the time of PICU admission, 43 patients were not colonized with MRSA but had an institutional history of MRSA colonization or infection; they were categorized as not colonized on admission.

Overall, 56 patients (1.8%) developed a subsequent MRSA infection, including 13 of 153 children colonized on admission (8.5%; 95% confidence interval [CI], 4.5%–14.5%) and 43 of 2987 (1.4%; 95% CI, 1.0–1.9%) not colonized on admission (relative risk [RR] 5.9; 95% CI, 3.4–10.1) [See Figure 1]. Compared with noncolonized children, MRSA-colonized children had an increased risk of respiratory infections (RR 5.3; 95% CI, 2.4–11.8) and nonrespiratory infections (RR 6.5; 95% CI, 3.1–13.6). Of 56 infections, 46 (82%) occurred after hospital discharge, 22 (39%) during subsequent inpatient visits and 24 (43%) during outpatient visits. Of the 42 patients known to be previously colonized with MRSA but not colonized with MRSA at time of admission, 4 (9.5%) developed a MRSA infection, but the risk in this group was not significantly different from that in those colonized at time of PICU admission (RR 1.12; 95% CI, 0.4–3.3).

Of all the patients, 10 (0.3%) developed a subsequent MRSA infection during their hospitalization, including 3 of 153 (1.9%; 95% CI, 0.4%–5.7%) children colonized on admission and 7 of 2987 (0.2%; 95% CI, .09%–.5%) not colonized on admission (RR 8.4; 95% CI, 2.7–25.8). Of the 42 patients previously colonized with MRSA and not colonized with MRSA at time of admission, none developed an infection during their hospitalization. The incidence rate of subsequent MRSA infections was higher in the colonized group (1.6 per 1000 patient-days) than in the noncolonized group (0.2 per 1000 patient-days) (incidence rate ratio [IRR] 6.9; 95% CI, 1.1–30.1). Patients colonized with MRSA on admission had a shorter time to development of a subsequent MRSA infection compared with those not colonized (P < .01 by log-rank test) (Supplementary Figure 1).

Of the children with subsequent MRSA infections, the median age was 4 years at time of PICU admission (See Table 2). African-Americans were at increased risk for a subsequent

Table 1. Clinical and Demographic Characteristics of Critically Ill Children Screened for Methicillin-Resistant Staphylococcus aureus Colonization at Time of Intensive Care Unit Admission

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total number of patients</th>
<th>Median age, years (IQR)</th>
<th>Male sex, no. (%)</th>
<th>Race, no. (%)</th>
<th>ZIP code of residence, no. (%)</th>
<th>Insurance, no. (%)</th>
<th>MRSA colonized or infected at time of PICU admission, number (%)</th>
<th>Previously but not currently MRSA Colonized at time of PICU admission, no. (%)</th>
<th>Underlying conditions,* n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total number of patients</td>
<td>3140</td>
<td>5.8 (1.0–12.8)</td>
<td>1744 (56)</td>
<td>Caucasian</td>
<td>1637 (52)</td>
<td>1668 (53)</td>
<td>153 (4.9)</td>
<td>43 (1.3)</td>
<td>Neurormuscular 1019 (32.4)</td>
</tr>
<tr>
<td>Median age, years (IQR)</td>
<td></td>
<td></td>
<td></td>
<td>African-American</td>
<td>1106 (35)</td>
<td>1421 (45)</td>
<td></td>
<td></td>
<td>Cardiovascular 704 (22.4)</td>
</tr>
<tr>
<td>Male sex, no. (%)</td>
<td></td>
<td></td>
<td></td>
<td>Other</td>
<td>397 (13)</td>
<td>40 (1)</td>
<td></td>
<td></td>
<td>Respiratory 193 (6.1)</td>
</tr>
<tr>
<td>Race, no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Renal 130 (4.1)</td>
</tr>
<tr>
<td>ZIP code of residence, no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Gastrointestinal 75 (2.4)</td>
</tr>
<tr>
<td>Insurance, no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hematologic deficiencies and immunodeficiencies 161 (5.1)</td>
</tr>
<tr>
<td>MRSA colonized or infected at time of PICU admission, number (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Metabolic 139 (4.4)</td>
</tr>
<tr>
<td>Previously but not currently MRSA Colonized at time of PICU admission, no. (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Congenital and genetic 391 (12.5)</td>
</tr>
<tr>
<td>Underlying conditions,* n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Malignancy 351 (11.2)</td>
</tr>
<tr>
<td>Underlying conditions,* n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>None 1155 (36.8)</td>
</tr>
<tr>
<td>Length of hospital stay, median (IQR), days</td>
<td></td>
<td>5 (4–11)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Length of ICU stay, median (IQR), days 1.8 (1.0–3.7)</td>
</tr>
</tbody>
</table>

Abbreviations: ICU, intensive care unit; IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus; PICU, pediatric intensive care unit. * Some patients had >1 underlying condition.

Figure 1. Impact of methicillin-resistant Staphylococcus aureus (MRSA) colonization on risk of subsequent infection in critically ill children. The risk of developing a subsequent MRSA infection was compared for children with and without MRSA colonization at time of admission to the pediatric intensive care unit. Patients were monitored for an infection during their hospitalization and after hospital discharge.
infection compared with non–African-American patients (2.8 vs 1.3%; \( P < .01 \)). Patients who lived in Baltimore City and those with public insurance were at increased risk for a subsequent MRSA infection (2.5% vs 1.4%; \( P = .03 \) and 2.5% vs 1.2%; \( P = .03 \), respectively). Most subsequent infections (50%) were respiratory infections, including pneumonia and tracheitis. There was only 1 bloodstream infection identified during the entire follow-up period.

To identify patients who acquired MRSA in the PICU, MRSA surveillance cultures from the naris were sent weekly, and clinical cultures from patients in the PICU for >3 days were monitored. During the study period, there were 15 incident MRSA cases in this cohort. Of these 15 patients, 7 (47%) developed a MRSA infection including 6 (40%) during their hospitalization. Patients who acquired MRSA in the PICU had a higher risk of infection compared with those colonized with MRSA at the time of PICU admission (RR 5.5; 95% CI, 2.5–11.8) and those not colonized with MRSA at the time of PICU admission (RR 32.4; 95% CI, 19.7–53.4). Combining those colonized on admission and those who acquired MRSA in the PICU, 20 of 168 (11.9%) patients known to be colonized during their hospitalization developed a subsequent MRSA infection.

Of the 153 patients colonized on admission, 133 (87%) had isolates available for PFGE analysis. Of these, 72 (61%) isolates were CA-MRSA strains identical to or related to PFGE types USA300, and 61 were non–CA-MRSA strains related to USA100 (\( n = 20 \)), USA200 (\( n = 1 \)), USA700 (\( n = 2 \)), USA1100 (\( n = 2 \)), or 21 other strains with unique PFGE fingerprints (\( n = 36 \)). Phenotypic data were available on isolates from patients with a subsequent infection. CA-MRSA strains caused 35 (63%) infections and non CA-MRSA caused 21 (37%). Of the colonized patients who developed a subsequent infection, 7 colonized with USA300-related strains developed an infection with CA-MRSA strains. 5 patients colonized with USA100-related strains became infected, 4 with non–CA-MRSA strains and 1 with a CA-MRSA strain.

**DISCUSSION**

MRSA-colonized adults are at increased risk of developing a MRSA infection, but data are limited in children. We found that critically ill children colonized with MRSA were at significantly higher risk of subsequent MRSA infection than those not colonized with MRSA. Patients who acquired MRSA in the hospital were at greatest risk of developing a MRSA infection. This highlights the importance of preventing nosocomial MRSA transmission. Importantly, most infections (82%) occurred after hospital discharge. Genotypic and phenotypic data suggest that subsequent infections may be caused by endogenous colonizing strains in most cases.

Our data confirm observations in hospitalized adults that MRSA-colonized patients have an increased risk of subsequent MRSA infection compared with those not colonized with MRSA [13, 14]. Davis and colleagues reported a 9.5-fold increased risk of subsequent infection in critically ill adults colonized with MRSA compared with those not colonized with MRSA [13]. Similarly, we found an 8.4-fold increased risk in those colonized to develop an infection during their hospital admission and a 5.9-fold increased risk during their hospitalization and after discharge. Children who acquired MRSA in our PICU had a significantly greater chance of a subsequent MRSA infection compared with both those colonized and those not colonized at time of ICU admission. This increased risk of infection in those who acquire MRSA colonization in the ICU provides a strong argument for the importance of comprehensive strategies to prevent nosocomial MRSA transmission in children. Traditional MRSA-control strategies

---

**Table 2. Characteristics of 56 Patients With Subsequent Methicillin-Resistant Staphylococcus aureus Infections**

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at time of PICU admission, median years (IQR)</td>
<td>4 (0.8, 12)</td>
</tr>
<tr>
<td>Race</td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>21 (38%)</td>
</tr>
<tr>
<td>African-American</td>
<td>30 (54%)</td>
</tr>
<tr>
<td>Other</td>
<td>5 (8%)</td>
</tr>
<tr>
<td>MRSA colonized or infected at time of PICU admission, no. (%)</td>
<td>13 (23.2)</td>
</tr>
<tr>
<td>Length of hospital stay, median (IQR) days</td>
<td>9.5 (6–25.5)</td>
</tr>
<tr>
<td>Length of ICU stay, median (IQR) days</td>
<td>2.5 (1.7–7.7)</td>
</tr>
<tr>
<td>Zip code of residence, no. (%)</td>
<td></td>
</tr>
<tr>
<td>Baltimore City</td>
<td>25 (45)</td>
</tr>
<tr>
<td>Other</td>
<td>31 (55)</td>
</tr>
<tr>
<td>Insurance, no. (%)</td>
<td></td>
</tr>
<tr>
<td>Private</td>
<td>20 (36)</td>
</tr>
<tr>
<td>Public</td>
<td>36 (64)</td>
</tr>
<tr>
<td>Time to infection, median (IQR) days</td>
<td></td>
</tr>
<tr>
<td>Infections occurring during hospitalization (n = 10)</td>
<td>8.5 (5–19)</td>
</tr>
<tr>
<td>Infections occurring during entire follow-up (n = 56)</td>
<td>195 (37, 511)</td>
</tr>
<tr>
<td>Site of infection</td>
<td></td>
</tr>
<tr>
<td>Pneumonia</td>
<td>9 (16%)</td>
</tr>
<tr>
<td>Other respiratorya</td>
<td>19 (34%)</td>
</tr>
<tr>
<td>Skin and soft tissue</td>
<td>13 (23%)</td>
</tr>
<tr>
<td>Surgical site infection</td>
<td>10 (18%)</td>
</tr>
<tr>
<td>Other</td>
<td>3 (5%)</td>
</tr>
<tr>
<td>Bloodstream</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Central nervous system</td>
<td>1 (2%)</td>
</tr>
</tbody>
</table>

Abbreviations: ICU, intensive care unit; IQR, interquartile range; MRSA, methicillin-resistant Staphylococcus aureus; PICU, pediatric intensive care unit.

a Included tracheitis and tracheobronchitis (\( n = 18 \)) and tonsillitis with abscess (\( n = 1 \)).
including patient isolation have been criticized, as isolated
patients may experience more adverse events, be less likely
to have vital signs recorded, and have more days without a phy-
sician progress note than nonisolated patients [30–32]. Isola-
tion may create a feeling of social isolation and stigma for
patients colonized with MRSA [18]. Therefore, given the high
risk of infection in patients who acquire MRSA colonization in
the hospital, future studies must identify strategies for MRSA
prevention that have the least impact on the delivery of care
to children.

Similar to hospitalized adults, critically ill children colonized
with MRSA have a significant risk of developing a MRSA in-
fec tion. Overall, 11.9% of children colonized with MRSA in
the ICU developed a MRSA infection, including 8.5% of those
colonized on admission and 47% of those who acquired MRSA
in the ICU. Subsequent rates of infection in adults have ranged
from 19%–30% [13, 15]. Rates of infection may be lower in
children who have fewer underlying complex chronic con-
ditions and shorter lengths of ICU stay. Critically ill adults on
average have greater severity of illness and a higher device
utilization rate, which may increase the risk of infection during
hospitalization. This hypothesis is supported by a study of
neonates in the ICU, a population with prolonged ICU stays
and high device-use rates, in which 26% of colonized neonates
developed an MRSA infection [33].

Consistent with previous findings, our data showed that many
MRSA infections occur after hospital discharge [11]. Caregivers
of children colonized with MRSA frequently have concerns
about their child’s risk of subsequent infection [18]. Our data
will enable healthcare workers to counsel families about the
risks during the child’s hospitalization and after discharge.
Strategies to decrease the risk of infection following discharge,
such as decolonization, should be considered.

Our data confirm findings from previous studies that have found racial disparities in rates of invasive MRSA disease
[3, 34, 35]. Klevens et al found that African-Americans had
a higher incidence of invasive MRSA disease than Caucasians
and mortality rates that were 80% higher [11]. The reason for
these racial disparities is unknown. Previous pediatric studies
in hospitalized and healthy children found African-Americans
were more likely to have MRSA colonization [20, 36]. Because
colonization is a known risk factor for invasive MRSA disease,
higher colonization rates in African-Americans may in part
explain a disproportionate rate of invasive disease in this group.
Findings from our study may help to explain this association.
Our data suggest that those with public insurance had an in-
creased risk of infection. Public insurance may represent lower
socioeconomic status. Although this study was not designed to
identify independent risk factors for infection, after adjusting
for insurance status, the association between race and infection
was no longer significant (data not shown). Therefore, although
African-Americans are more likely to develop an MRSA in-
fec tion, other important characteristics, such as socioeconomic
status, may explain the association between race and infection.
Additional large studies are needed to explore racial disparities
in MRSA colonization and infection.

CA-MRSA strains, especially PFGE type USA300, continue to
be the most common MRSA strain colonizing children admitted
to our PICU. We found that 61% of children colonized with
MRSA at the time of PICU admission harbored a CA-MRSA
strain. The high prevalence of USA300 strains may be multi-
factorial. First, the community prevalence of MRSA coloniza-
tion in children is increasing in the Baltimore community
and nationwide [1, 2, 20, 28, 37], in large part because of the
spread of CA-MRSA strains. Second, children generally have
less-frequent exposure to healthcare facilities and traditional
HA-MRSA strains. Third, children routinely are in close contact
environments where opportunities for hygiene may be limited,
such as day care, schools, and sports teams, areas postulated as
high-risk environments for MRSA transmission. All patients
colonized with CA-MRSA strains developed infections with
strains with a CA-MRSA phenotype. Similarly, 80% of chil-
dren colonized with non–CA-MRSA developed infection with
a non–CA-MRSA phenotype. In this small sample of colonized
patients who developed subsequent infection, the concordance
of colonizing and infecting strains was high.

Several limitations should be considered when interpreting
our data. First, only naris cultures were performed to identify
asymptomatic MRSA carriers at the time of admission to the
PICU. Studies have shown screening extranasal anatomic sites,
such as throat, axilla, perineum and stool can increase the de-
tection of MRSA carriers [38, 39], especially those colonized
with CA-MRSA strains. Therefore, we may have misclassified
colonized patients as noncolonized, including those with a his-
tory of MRSA colonization that had a negative naris culture on
admission. Thus the infection rate in those not colonized on
admission may have been overestimated. Second, we likely un-
derestimated rates of infection after hospital discharge as we
relied on inpatient and outpatient cultures processed in our
institution’s clinical microbiology laboratory. We did not cap-
ture infections that occurred at other healthcare facilities. We
do not think that this would have led to a differential bias be-
tween children colonized and not colonized on admission to
the ICU as a similar percentage of both groups (76% and 79%)
visited our institution during the follow-up period. Third, we
had relatively few events, so confirming these findings in
another cohort would support the conclusions. Finally, we in-
cluded only patients admitted to the PICU, so our findings may
not be generalizable to non-ICU populations.

Overall, our study found that MRSA colonization increased
the risk of subsequent MRSA infection in children. Children
who acquired MRSA in the ICU were at especially high risk,
further emphasizing the need to prevent nosocomial transmission of MRSA. A high risk of infection in select groups of children offers an opportunity to intervene to prevent MRSA infections. MRSA decolonization is not standard practice in hospitalized children. Future studies should address not just interventions to protect the population from MRSA transmission, but interventions such as decolonization to protect the individual child from subsequent infection.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online (http://www.oxfordjournals.org/our_journals/cid/). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copyedited. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. We thank Sonali Advani and Alicia Budd for their assistance, The JHH Microbiology laboratory staff, the JHH PICU nursing staff, and The JHH Hospital Epidemiology and Infection Control Group for their support of this study.

Financial support. This work was supported by the National Institute for Allergy and Infectious Diseases at the National Institutes of Health (K23 AI081752-02 to A. M.); and Johns Hopkins School of Medicine for Allergy and Infectious Diseases at the National Institutes of Health (K23 AI081752-02 to A. M.).

Potential conflicts of interest. A. M. and T. P. received grant support from Sage Products. A. M. received grant support from BioMerieux. T. P. received grant support from Merck and is on Advisory Boards for Hospira and BioMerieux. K. C. has received research funds from BD Diagnostics, Akonni, and Microphage, and is on the Scientific Advisory Boards of Quidel and NanoMR. All other authors report no potential conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

25. Murray BE, Singh KV, Heath JD, Sharma BR, Weinstock GM. Comparison of genomic DNAs of different enterococcal isolates using restriction


